GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
1.807
-0.003 (-0.19%)
Aug 4, 2025, 11:35 AM - Market open
Altair Engineering Employees
GT Biopharma had 1 employees as of December 31, 2024. The number of employees decreased by 1 or -50.00% compared to the previous year.
Employees
1
Change (1Y)
-1
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$11,672,000
Market Cap
5.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1 | -1 | -50.00% |
| Dec 31, 2023 | 2 | 0 | - |
| Dec 31, 2022 | 2 | -6 | -75.00% |
| Dec 31, 2021 | 8 | 5 | 166.67% |
| Dec 31, 2020 | 3 | 1 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GTBP News
- 7 weeks ago - GT Biopharma Appoints New Member to its Board of Directors - GlobeNewsWire
- 2 months ago - GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - GlobeNewsWire
- 5 months ago - GT Biopharma Announces Exercise of Warrants - GlobeNewsWire
- 9 months ago - GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 11 months ago - GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 11 months ago - GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 - GlobeNewsWire
- 1 year ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia - GlobeNewsWire
- 1 year ago - GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire